
Operations Office

Telephone (507) 266-3465



Date: January 25, 2008

To: Primary Clinical Research Associates

From: Daniel V. Satele
Protocol Development Coordinator

Re: **N06CA, The Use of Topical Baclofen, Amitriptyline HCl, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study**

The enclosed protocol is being prepared for activation and it is anticipated that it will activate within a few weeks. You may submit this protocol to your IRB for review.

We will notify you of protocol activation via an activation amendment that will include any changes not included in the enclosed version. A forms packet will be included at that time.

If you have any questions, please feel free to contact me.

Enclosure